Passage Bio Tapped Kathleen Borthwick as CFO, Effective March 1
Portfolio Pulse from Benzinga Newsdesk
Passage Bio has appointed Kathleen Borthwick as its new Chief Financial Officer, effective March 1, 2024. Borthwick, who has 25 years of experience in pharmaceutical and biotech financial leadership, previously served as the company's Senior Vice President, Finance and Interim CFO.
March 04, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kathleen Borthwick's appointment as CFO of Passage Bio, effective March 1, 2024, brings experienced financial leadership to the company.
The appointment of a CFO with extensive experience in the pharmaceutical and biotech sectors is likely to be viewed positively by investors, as it suggests that Passage Bio is strengthening its financial leadership. This could lead to improved financial strategies and potentially better financial performance in the future, positively impacting the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90